In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Duker about a sustained-release tyrosine kinase inhibitor that could redefine the durability and convenience of anti-VEGF therapy.
Jay S. Duker, MD
Advertisement
Articles by Jay S. Duker, MD
Study aims to identify methodology for least amount of variation, greatest test-retest reliability
Advertisement
Latest Updated Articles
Parafoveal retinal vessel density assessment by OCTA in healthy eyesPublished: July 25th 2018 | Updated:
Advertisement
Advertisement
Trending on Modern Retina
1
FLORetina 2025: AI at the forefront of ROP care
2
AAO 2025 Takeaways: The next frontier in retinal therapeutics arrives
3
Prevent Blindness delegates first week of December as 5th annual geographic atrophy week
4
EYDENZELT, Celltrion’s biosimilar referencing EYLEA, approved in Canada
5
